Fungal infections remain important opportunistic pathogens, particularly in immunocompromised individuals. A variety of fungal pathogens have been identified that cause infection in the growing population of immunocompromised patients. Over the last year, there have been further studies in the prophylactic, empiric, and therapeutic use of various antifungal agents to provide guidance in management. There have also been studies in the development of new serologies for diagnosis and therapeutic decisions for certain mycoses. Finally, new specific therapies or regimens to help the host immune system have been successfully used in certain high-risk patients.
展开▼
